FCMI
TPST icon

Foresite Capital Management IV’s Tempest Therapeutics TPST Stock Holding History

Foresite Capital Management IV’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,632
Closed -$2.75M – 11
2021
Q3 		$2.75M Hold
14,632
– – 0.41% 11
2021
Q2 		$2.13M Buy
+14,632
New +$3.29M 0.29% 13

Other funds holding TPST

RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Foresite Capital Management IV's TPST Position: Q4 2021 in Review

Foresite Capital Management IV sold out of Tempest Therapeutics (TPST) in Q4 2021, closing a stake of 14,632 shares — an estimated $2.75M sold.

Foresite Capital Management IV first reported a position in TPST in Q2 2021 and held it in 2 quarters. The position peaked at $2.75M in Q3 2021. 17 funds tracked by Wall St. Rank hold TPST as of Q4 2021.

  • Foresite Capital Management IV reported no remaining Tempest Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Foresite Capital Management IV sold 14,632 Tempest Therapeutics shares in Q4 2021, an estimated $2.75M.
  • Foresite Capital Management IV first reported a position in Tempest Therapeutics in Q2 2021 and held it in 2 quarters.
  • Foresite Capital Management IV's Tempest Therapeutics position peaked at $2.75M in Q3 2021.
  • 17 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2021.

Based on Foresite Capital Management IV's 13F filing for Q4 2021, filed 11 Feb 2022.